Nature Communications (Jan 2019)
Post-exposure immunotherapy for two ebolaviruses and Marburg virus in nonhuman primates
- Jennifer M. Brannan,
- Shihua He,
- Katie A. Howell,
- Laura I. Prugar,
- Wenjun Zhu,
- Hong Vu,
- Sergey Shulenin,
- Shweta Kailasan,
- Henna Raina,
- Gary Wong,
- Md Niaz Rahim,
- Logan Banadyga,
- Kevin Tierney,
- Xuelian Zhao,
- Yuxing Li,
- Frederick W. Holtsberg,
- John M. Dye,
- Xiangguo Qiu,
- M. Javad Aman
Affiliations
- Jennifer M. Brannan
- US Army Medical Research Institute of Infectious Diseases
- Shihua He
- Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada
- Katie A. Howell
- Integrated BioTherapeutics, Inc.
- Laura I. Prugar
- US Army Medical Research Institute of Infectious Diseases
- Wenjun Zhu
- Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada
- Hong Vu
- Integrated BioTherapeutics, Inc.
- Sergey Shulenin
- Integrated BioTherapeutics, Inc.
- Shweta Kailasan
- Integrated BioTherapeutics, Inc.
- Henna Raina
- Integrated BioTherapeutics, Inc.
- Gary Wong
- Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada
- Md Niaz Rahim
- Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada
- Logan Banadyga
- Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada
- Kevin Tierney
- Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada
- Xuelian Zhao
- Department of Microbiology and Immunology, University of Maryland School of Medicine
- Yuxing Li
- Department of Microbiology and Immunology, University of Maryland School of Medicine
- Frederick W. Holtsberg
- Integrated BioTherapeutics, Inc.
- John M. Dye
- US Army Medical Research Institute of Infectious Diseases
- Xiangguo Qiu
- Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada
- M. Javad Aman
- Integrated BioTherapeutics, Inc.
- DOI
- https://doi.org/10.1038/s41467-018-08040-w
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 10
Abstract
Current experimental monoclonal antibodies (mAbs) for Ebola virus (EBOV) post-exposure immunotherapy are ineffective against Sudan (SUDV) or Marburg virus (MARV). Here, authors develop cocktails of mAbs that protect nonhuman primates against EBOV, SUDV, and MARV infection when given four days post infection.
